ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Return on equity 2016–2025
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-0.3%FY2025 · since FY2016: -85.5% → -0.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -0.3% | +322.9 pp |
| FY2024 | -323.3% | -247.6 pp |
| FY2023 | -75.7% | -31.5 pp |
| FY2022 | -44.2% | -9.7 pp |
| FY2021 | -34.5% | -16.1 pp |
| FY2020 | -18.3% | -46.1 pp |
| FY2019 | 27.8% | +84.6 pp |
| FY2018 | -56.8% | -14.6 pp |
| FY2017 | -42.2% | +43.3 pp |
| FY2016 | -85.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ARWR financial trends
ARWR RevenueARWR Net incomeARWR Net marginARWR Gross profitARWR Gross marginARWR Operating incomeARWR Operating marginARWR Operating cash flowARWR Free cash flowARWR Capital expendituresARWR Stock buybacksARWR Dividends paidARWR Total assetsARWR Total liabilitiesARWR Shareholders’ equityARWR overview →